ArticleJournal of Korean medical science2022

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea.

Myeong Geun Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.